Quintiles is the industry leader that best differentiates itself on service quality in phase II/III clinical research, according to 157 pharmaceutical and biotechnology professionals who responded to Industry Standard Research’s (ISR).

Respondents also rated Quintiles as the leader among large CROs for customer loyalty, defined by overall satisfaction, willingness to recommend and likelihood to use Quintiles again, according to the 2013 CRO Quality Benchmarking Report phase II/III.

“We are deeply committed to helping our customers increase their probability of success at every stage of the product life cycle and delighted to see that our commitment in customer satisfaction are recognized by the industry,” said Paula Brown Stafford, president, Clinical Development, Quintiles.

According to the report, Quintiles is the best phase II/III clinical research service provider at differentiation based on service quality. The company also leads in the  large CROs category in customer loyalty and is the most cited industry leader.

Survey respondents also recognised Quintiles as a leader among large CROs for meeting customer expectations for real-time access to data. The company has been able to transform drug development through its data and proprietary knowledge engine, Quintiles Infosario, an innovative solution that seamlessly integrates data.